Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients

被引:47
|
作者
Sanchez-Conde, M. [1 ]
Miralles, P. [1 ]
Maria Bellon, J. [2 ]
Rincon, D. [3 ]
Ramirez, M. [1 ]
Gutierrez, I. [1 ]
Ripoll, C. [3 ]
Lopez, J. C. [1 ]
Cosin, J. [1 ]
Clemente, G. [3 ]
Lo Iacono, O. [3 ]
Banares, R. [3 ,4 ]
Berenguer, J. [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Infect Dis & HIV Unit, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Biomed Res Fdn, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Hepatol Unit, Madrid, Spain
[4] Spanish CIBERehd Res Grp, Barcelona, Spain
关键词
hepatitis C infection; HIV infection; liver cirrhosis; liver pathology; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; VENOUS-PRESSURE GRADIENT; STAGE LIVER-DISEASE; INFECTED PATIENTS; THERAPEUTIC STRATEGIES; NATURAL-HISTORY; FIBROSIS; CIRRHOSIS; PROGRESSION;
D O I
10.1111/j.1365-2893.2010.01371.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure and correlates with the occurrence of portal hypertension (PH)-related complications. Transient elastography (TE) is a new, highly accurate noninvasive technique, which enables us to evaluate hepatic fibrosis to detect advanced fibrosis and cirrhosis. We performed a hepatic haemodynamic study and TE in 38 HIV/HCV-coinfected patients. The association between HVPG and liver stiffness was assessed by linear regression. The diagnostic value of TE was assessed by receiver operating characteristic (ROC) curves. We considered clinically significant PH as an HVPG >= 10 mmHg and severe PH as an HVPG 12 mmHg. A total of 38 HIV/HCV-coinfected patients were included. Twenty-eight patients (73.7%) had clinically significant PH (HVPG >= 10 mmHg), and 23 (60.5%) of these had severe PH (HVPG >= 12 mmHg). We found a statistically significant association between liver stiffness (kPa) and HVPG(r(2) = 0.46, P < 0.001, straight line equation HVPG = 7.4 + 0.204*TE). The areas under the ROC curves were 0.80 [95% confidence interval (CI), 0.64-0.97] and 0.80 (95% CI, 0.66-0.94) for the prediction of HVPG 10 and 12 mmHg, respectively. Our data suggest that TE can predict the presence of clinically significant and severe PH in HIV/HCV-coinfected patients.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 50 条
  • [1] Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCV-Coinfected Patients in Clinical Practice
    Jose Lopez, Juan
    Perez-Alvarez, Nuria
    Rodriguez, Raul V.
    Jou, Antoni
    Carbonell, Pere
    Jimenez, Jose A.
    Soldevila, Laura
    Tenesa, Montserrat
    Tor, Jordi
    Clotet, Bonaventura
    Bechini, Jordi
    Tural, Cristina
    JOURNAL OF ULTRASOUND IN MEDICINE, 2018, 37 (01) : 113 - 121
  • [2] Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
    Perez-Latorre, Leire
    Sanchez-Conde, Matilde
    Miralles, Pilar
    Carlos Lopez, Juan
    Parras, Francisco
    Tejerina, Francisco
    Aldamiz-Echevarria, Teresa
    Carrero, Ana
    Diez, Cristina
    Ramirez, Margarita
    Gutierrez, Isabel
    Maria Bellon, Jose
    Banares, Rafael
    Berenguer, Juan
    BMC INFECTIOUS DISEASES, 2018, 18
  • [3] Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry
    Neukam, Karin
    Recio, Eva
    Camacho, Angela
    Macias, Juan
    Rivero, Antonio
    Mira, Jose A.
    Lopez, Cristina
    Almeida, Carmen
    de la Torre, Julian
    Pineda, Juan A.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (07) : 801 - 807
  • [4] Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life
    Ingiliz, Patrick
    FUTURE VIROLOGY, 2013, 8 (08) : 735 - 743
  • [5] Genetic Polymorphisms Associated with Liver Disease Progression in HIV/HCV-Coinfected Patients
    Medrano, Luz M.
    Jimenez-Sousa, Maria A.
    Fernandez-Rodriguez, Amanda
    Resino, Salvador
    AIDS REVIEWS, 2017, 19 (01) : 3 - 15
  • [6] Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients
    Frias, Mario
    Rivero-Juarez, Antonio
    Lopez-Lopez, Pedro
    Rivero, Antonio
    PHARMACOGENOMICS, 2018, 19 (12) : 979 - 995
  • [7] Therapeutic issues in HIV/HCV-coinfected patients
    Sulkowski, M. S.
    Benhamou, Y.
    JOURNAL OF VIRAL HEPATITIS, 2007, 14 (06) : 371 - 386
  • [8] Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
    Garcia-Broncano, Pilar
    Maria Medrano, Luz
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Angeles Jimenez-Sousa, Ma
    Carrero, Ana
    Hontanon, Victor
    Guardiola, Josep M.
    Crespo, Manuel
    Quereda, Carmen
    Sanz, Jose
    Belen Garcia-Gomez, Ana
    Luis Jimenez, Jose
    Resino, Salvador
    CELLS, 2018, 7 (11)
  • [9] Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients
    Arenzana, Carmen Busca
    Gonzalez-Garcia, Juan
    Blas-Garcia, Ana
    V. Esplugues, Juan
    Martin, Antonio Olveira
    Ramirez, Maria Luisa Montes
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2024, 42 (02): : 74 - 79
  • [10] HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
    Brochado-Kith, Oscar
    Martinez, Isidoro
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Salguero, Sergio
    Sepulveda-Crespo, Daniel
    Diez, Cristina
    Hontanon, Victor
    Ibanez-Samaniego, Luis
    Perez-Latorre, Leire
    Fernandez-Rodriguez, Amanda
    angeles Jimenez-Sousa, Maria
    Resino, Salvador
    FRONTIERS IN IMMUNOLOGY, 2021, 12